Flavin-containing dimethylaniline monooxygenase 6, pseudogene (FMO6P)

The FMO6P gene, also known as Flavin-containing dimethylaniline monooxygenase 6, pseudogene, is a member of the flavin-containing monooxygenase (FMO) family. FMOs are enzymes involved in the oxygenation of drugs and xenobiotics, typically via N- or S-oxidation, and contribute significantly to phase I metabolism of xenobiotics in humans[3][5][6]. However, unlike other FMOs (such as FMO1–5), the FMO6P gene is a pseudogene and does not encode a functional enzyme in humans. In other species, related FMO6 orthologs may retain enzymatic activity, but the human FMO6P gene product is nonfunctional, and there is no evidence of any physiological activity, disease association, or drug interactions. Thus, FMO6P is not considered a valid therapeutic target in human biology[5][7]. Key Points: - FMO6P is a nonfunctional pseudogene in humans, distinguishing it from other functional FMO enzymes (FMO1–5)[5][7]. - The FMO family as a whole is important for drug and xenobiotic metabolism, but FMO6P does not contribute to these processes[3][5][6]. - Related FMO6 orthologs in other species may be functional, but this is not the case for humans[5]. - It is not a target for existing drugs, does not have measurable biological function, and is not associated with diseases or therapeutic research in humans[5][7]. In summary: FMO6P should not be considered a canonical therapeutic target in humans due to its pseudogene status, lack of protein product, and lack of any known biological activity or disease association.

Other names

Putative dimethylaniline monooxygenase [N-oxide-forming] 6FMO6PFMO6FMO 6Dimethylaniline oxidase 6Flavin-containing monooxygenase 6